Form 4: United Therapeutics COO Michael Benkowitz Executes Stock Option and Sells Shares

Michael Benkowitz, President and COO of United Therapeutics, exercised stock options and sold a portion of the acquired shares on November 1, 2024.

Summary

• On November 1, 2024, Michael Benkowitz, the President and COO of United Therapeutics, exercised stock options to acquire 14,700 shares of common stock at a price of $120.26 per share.
• Following the acquisition, Benkowitz sold a total of 14,700 shares of common stock through a series of transactions at prices ranging from $370.645 to $378.
• These sales were executed in multiple trades at weighted average prices.
• After these transactions, Benkowitz directly owns 2,577 shares and indirectly owns 0 shares through a trust.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's future.

Industry Context

This filing is a routine disclosure of insider transactions, which are common occurrences in publicly traded companies. Investors often monitor these filings to gain insights into management's perspective on the company's stock and future prospects.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders, as mandated by the SEC.
• The transactions are typical for executives who receive stock options as part of their compensation packages.
• Comparable companies such as Gilead Sciences, Amgen, and Biogen also have frequent Form 4 filings related to their executives' stock transactions.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal.

Key Dates